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Background: The thyroid gland has a special relationship with oxidative stress. While generation of oxidative
substances is part of normal iodide metabolism during thyroid hormone synthesis, the gland must also defend
itself against excessive oxidation in order to maintain normal function. Antioxidant and detoxification enzymes
aid thyroid cells to maintain homeostasis by ameliorating oxidative insults, including during exposure to excess
iodide, but the factors that coordinate their expression with the cellular redox status are not known. The
antioxidant response system comprising the ubiquitously expressed NFE2-related transcription factor 2 (Nrf2)
and its redox-sensitive cytoplasmic inhibitor Kelch-like ECH-associated protein 1 (Keap1) defends tissues
against oxidative stress, thereby protecting against pathologies that relate to DNA, protein, and/or lipid oxi-
dative damage. Thus, it was hypothesized that Nrf2 should also have important roles in maintaining thyroid
homeostasis.
Methods: Ubiquitous and thyroid-specific male C57BL6J Nrf2 knockout (Nrf2-KO) mice were studied. Plasma
and thyroids were harvested for evaluation of thyroid function tests by radioimmunoassays and of gene and
protein expression by real-time polymerase chain reaction and immunoblotting, respectively. Nrf2-KO and
Keap1-KO clones of the PCCL3 rat thyroid follicular cell line were generated using CRISPR/Cas9 technology
and were used for gene and protein expression studies. Software-predicted Nrf2 binding sites on the thyro-
globulin enhancer were validated by site-directed in vitro mutagenesis and chromatin immunoprecipitation.
Results: The study shows that Nrf2 mediates antioxidant transcriptional responses in thyroid cells and protects
the thyroid from oxidation induced by iodide overload. Surprisingly, it was also found that Nrf2 has a dramatic
impact on both the basal abundance and the thyrotropin-inducible intrathyroidal abundance of thyroglobulin
(Tg), the precursor protein of thyroid hormones. This effect is mediated by cell-autonomous regulation of Tg
gene expression by Nrf2 via its direct binding to two evolutionarily conserved antioxidant response elements in
an upstream enhancer. Yet, despite upregulating Tg levels, Nrf2 limits Tg iodination both under basal conditions
and in response to excess iodide.
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Conclusions: Nrf2 exerts pleiotropic roles in the thyroid gland to couple cell stress defense mechanisms to iodide
metabolism and the thyroid hormone synthesis machinery, both under basal conditions and in response to excess
iodide.
Keywords: Nrf2, thyroid, thyroglobulin, iodide, oxidative stress, animal testing alternatives
Introduction
Oxidative stress (OS) ensues when reactive speciesoverwhelm the cell’s antioxidant and detoxification
systems (1,2). In addition to protein and lipid damage, OS
causes mutations and epigenetic perturbations, thereby
leading to, or exacerbating, various diseases such as cancer,
neurodegeneration, ischemia–reperfusion injury, chronic
obstructive pulmonary disease, and many others. Disorders
linked to oxidation affect tissues that are exposed to the en-
vironment (e.g., the skin, lung, and digestive tract), generate
high amounts of free radicals (e.g., the muscle), function in
detoxification (e.g., the liver, kidney, and placenta), or are
particularly stress sensitive (e.g., neurons). In comparison,
relatively little is known about the role of OS in the thyroid,
an organ that generates high amounts of the oxidant hydrogen
peroxide (H2O2) to oxidize iodide (I
–, the anion of iodine)
and iodinate thyroglobulin (Tg) during the synthesis of thy-
roid hormones in the lumen of the spherical structures (fol-
licles) formed by thyroid follicular cells. It has been shown
that compared to other tissues, the thyroid has increased ca-
pacity to defend itself against OS (3). Specific antioxidant
and detoxification enzymes have been identified that pre-
sumably help thyroid cells to maintain homeostasis by
ameliorating oxidative insults, including glutathione perox-
idase 2 (Gpx2) and thioredoxin reductase 1 (Txnrd1) (4,5).
While a minimal oxidative load is necessary for normal
thyroid cell function (6,7), the gland’s antioxidant defense is
activated by intrathyroidal OS occurring during iodide defi-
ciency, goitrogenesis, or high iodide-induced involution of
goiter (5,8,9). Yet, it is not well understood which systems
allow thyrocytes to sense and respond to OS, and it is un-
known whether the antioxidant defense mechanisms are
coupled to the thyroid hormone synthesis process.
The ubiquitously expressed transcription factor NFE2-
related transcription factor 2 (Nrf2) is a plausible candidate
for mediating the thyroid’s antioxidant response. In the ab-
sence of OS, Nrf2 binds to its cytoplasmic inhibitor Kelch-
like ECH-associated protein 1 (Keap1) (10,11), which targets
Nrf2 for poly-ubiquitination and subsequent proteasomal
degradation. Keap1 also functions as a sensor of oxidants and
electrophiles, which react with its redox-sensitive cysteines
(12,13). Oxidative stressors abolish the inhibition of Nrf2 by
Keap1; Nrf2 then accumulates in the nucleus where it tran-
scriptionally activates protective genes through antioxidant
response elements (AREs) in their regulatory sequences (14–16).
Across the evolutionary spectrum, Nrf2 is required to defend
organisms against OS and to protect against stress-related
pathologies by preventing DNA, protein, and lipid oxidative
damage (17), functioning as a multi-organ protector (18).
In animal models of disease, pharmacological activation
of Nrf2 by various synthetic and natural compounds can
prevent cancer and other disorders linked to OS (19–21).
Regarding the thyroid, a recent preliminary study suggested
that Nrf2 is activated in the thyroid of rats in response to
exposure to pharmacological doses of iodide, but the poten-
tial physiological relevance of this phenomenon was not
addressed (22). Using ubiquitous and thyroid-specific Nrf2
knockout (Nrf2-KO) mice and Nrf2- or Keap1-KO thyroid
follicular cell lines, this study shows that Nrf2 mediates an-
tioxidant transcriptional responses in thyroid cells and pro-
tects the thyroid from oxidation induced by iodide overload.
Surprisingly, the study also found that Nrf2 has a dramatic
impact on both the basal abundance and the thyrotropin
(TSH)-inducible abundance of Tg in the thyroid. This effect
is mediated by direct, cell-autonomous regulation of Tg gene
expression by Nrf2 via two evolutionarily conserved AREs.
Thus, Nrf2 couples cell stress defense mechanisms to iodide
metabolism and the thyroid hormone synthesis machinery.
Methods
Nrf2 knockout mice
C57BL/6J Nrf2+/- mice (15) were obtained from RIKEN
BRC (Tsukuba, Japan). Nrf2 wild-type (WT) and knockout
(Nrf2-KO) mice were generated by mating Nrf2+/-males and
females. Offspring were genotyped, as previously described
(15). For iodide challenge, male WT and Nrf2-KO mice
(three to four months old) fed a standard diet were supplied
with normal tap water with or without 0.05% sodium iodide
(NaI) for seven days. Mice were housed in the animal facility
of the University of Patras Medical School in temperature-,
light-, and humidity-controlled rooms with a 12-hour light/
dark cycle. All animal procedures were approved by the local
Institutional Review Board and were in accordance with
European Commission Directive 86/609/EEC.
Nrf2 thyroid-specific KO mice
Mice expressing Cre recombinase under control of the
Pax8 locus (Pax8[Cre/+]) (23) were crossed with Nrf2 flox/
flox mice that harbor flox sites flanking the DNA-binding
domain (exon 5) of the Nrf2 gene (24). The resulting
Pax8(Cre/+)-Nrf2 flox/+ mice were backcrossed with Nrf2
flox/flox mice to obtain Pax8(Cre/+)-Nrf2 flox/flox mice,
hereafter referred to as thyroid-specific Nrf2 KO (ts-KO).
Pax8 and Nrf2 alleles were genotyped by polymerase chain
reaction (PCR) using primers and conditions described
in Supplementary Tables S1–S4 (Supplementary Data are
available online at www.liebertpub.com/thy). Thyroid-
specific Nrf2 disruption as a result of recombination of the
Nrf2 floxed allele was confirmed by genotyping thyroid
DNA. Real-time reverse transcription (RT)-PCR was also
used to confirm the thyroid-specific Nrf2 deletion using
primers targeting the exon 5 of Nrf2 (Supplementary
Table S5). Nrf2 flox/flox mice were used as a control group
in experiments. Mice were housed in the animal facility of
the Department of Physiology at the University of Lausanne
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in temperature-, light-, and humidity-controlled rooms with
a 12-hour light/dark cycle. All animal procedures were in
accordance with Swiss legislature and approved by the
Canton of Vaud SCAV.
Tissue collection
Mice were sacrificed by cervical dislocation immediately
before removal of the thyroid gland. Thyroids were surgically
dissected under a stereomicroscope and were immediately
submerged in RNAlater solution for RNA and protein iso-
lation or in 4% neutral-buffered formalin for tissue fixation
and subsequent histology. Blood was collected with cardiac
puncture.
Hormonal measurements
Plasma was collected using heparin- (Nrf2-KO mice and
controls) or EDTA-coated tubes (ts-KO mice and controls)
and was centrifuged at 2000 g for 20min at 4C. The dif-
ference in collection methods reflects the local practices in
the respective laboratories (University of Patras and Lau-
sanne University Hospital, respectively). Serum tests of
thyroid function, including TSH, total thyroxine (T4) and
total triiodothyronine (T3), were measured at the University
of Chicago, as previously described in detail (25). Briefly,
total T4 and T3 concentrations were measured in plasma with
a coated tube radioimmunoassay (RIA) lit (Siemens Medical
Solutions Diagnostics, Los Angeles, CA) adapted for mice
using 25 and 50 lL of plasma, respectively. TSH was mea-
sured in 50 lL of plasma using a sensitive, heterologous,
disequilibrium, double-antibody precipitation RIA. In one
experiment (Nrf2-KO vs. WT, with or without NaI), total T4
was also measured at the University of Patras using an
enzyme-linked immunosorbent assay kit (DET4105T100
Thyroxine (T4) Mouse/Rat; Demeditec Diagnostics, Kiel,
Germany).
RNA isolation and real-time PCR
Total RNA from thyroid tissue and from cell lines was
isolated using TRIzol (Invitrogen, Carlsbad, CA) and further
purified using the RNeasy mini-kit with DNAse digestion
(Qiagen, Valencia, CA). For thyroid tissue, cDNA was syn-
thesized using 250 ng of RNA and the SuperScript VILO
cDNA Synthesis Kit (Invitrogen). For cell lines, cDNA was
synthesized using 500 ng of RNA and the PrimeScript cDNA
Synthesis Kit (Takara Bio, Kusatsu, Japan). cDNA was di-
luted 20 times, and 5 lL was used for each reaction of 15 lL
final volume. Real-time PCRs were performed on StepOne-
Plus or ViiA 7 Real-Time PCR System instruments (Applied
Biosystems, Foster City, CA) using FAST SYBR green
(Kapa Biosystems, Woburn, MA) under the following
conditions: 3min at 95C, followed by 40 cycles of 10 s at
95C and 25 s at 60C. The primers used are shown in
Supplementary Table S5. Melting curve analysis was used
to confirm gene-specific amplification. Gene expression in
thyroid tissues was quantified using relative standard curves
derived from serial dilutions of pooled cDNAs with Foxe1
as the reference gene. Foxe1 was selected based on deep-
sequencing data (not included in this study) showing no
change in its expression levels between KO and WT mice
with or without NaI treatment. Relative gene expression in
cell lines was quantified by the comparative cycle threshold
method using Rpl19 as the reference gene.
Protein isolation, Western immunoblotting,
immunohistochemistry, and analysis
of protein oxidation
Total protein isolation from mouse thyroid tissues was
performed with simple modifications of the TRIzol manu-
facturer’s protocol published recently by the authors (26).
Briefly, the manufacturer’s protocol is followed until the
precipitation of proteins from the phenol–ethanol superna-
tant, at which step the protein pellet is completely dissolved
in 50–100 lL of 7M GndCl solution, and then proteins are
precipitated again by adding 1900 lL of 100% ethanol. This
step is repeated, followed by a final wash of the protein pellet
with 100% ethanol. After a 10min air-drying period, the
protein pellet is solubilized in 100–200lL of buffer of 8M
urea, 40mM of Tris, pH 8, 1% sodium dodecyl sulfate (SDS),
and 1· Halt protease inhibitor cocktail (Thermo Fisher Sci-
entific, Ecublens, Switzerland). Total protein extracts from
PCCL3 cells were prepared using RIPA buffer (50mM of
Tris, pH 8, 150mM of NaCl, 1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% SDS) supplemented with protease in-
hibitor cocktail and 5 lM of MG-132. Protein concentration
in all samples was measured by the Pierce BCA protein assay
kit (Thermo Fisher Scientific).
For Western blots, 20 lg (cell protein extracts) or 10lg
(thyroid protein extracts, 50 ng for the detection of Tg) was
used, and they were performed as previously described
(27) with minor modifications. Briefly, protein extracts were
resolved on Bis-Tris-MOPS polyacrylamide gels or Tris-
glycine sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE), followed by electrotransfer onto
polyvinylidene fluoride membranes (Amersham Biosciences,
Little Chalfont, United Kingdom) with Tris-Bicine Transfer
Buffer (25mM of Bicine, 25mM of Bis-Tris, 1mM of
EDTA, pH 7.2). Membranes were blocked at least 2 h with
5% nonfat dry milk in TBST (10mM of Tris-HCl, pH 7.4,
150mM of NaCl, 0.1% Tween 20), and incubated overnight
with the indicated antibodies. After incubation with a
horseradish peroxidase-conjugated secondary antibody, im-
munoreactive bands were visualized by WesternBright ECL
(cell extracts) or WesternBright Sirius (tissue extracts) (Ad-
vansta, Menlo Park, CA), and recorded using a CCD image
sensor (ChemiDoc XRS, Bio-Rad Laboratories, Cressier,
Switzerland) or exposed to X-ray film (Fuji RX; Fujifim,
Tokyo, Japan). The following primary antibodies were used:
antithyroglobulin (A0251, 1:10,000; Dako, Glostrup, Den-
mark); anti-TG-I (28) (1:3000); anti-NIS (29) (1:5000); anti-
Nrf2 (sc-13032, 1:1000; Santa Cruz Biotechnology, Dallas,
TX); anti-BiP (3183, 1:1000; Cell Signaling Technology,
Danvers, MA), anti-PERK (3192, 1:1000; Cell Signaling
Technology); anti-Phospho-PERK (Thr980; 3179, 1:1000;
Cell Signaling Technology); anti-SAPK/JNK (9252, 1:1000;
Cell Signaling Technology); anti-Phospho-SAPK/JNK
(Thr183/Tyr185; 9251, 1:1000; Cell Signaling Technology);
anti-Atg12 (4180, 1:1000; Cell Signaling Technology); anti-
Beclin-1 (3738, 1:1000; Cell Signaling Technology); anti-
LC3B (2775, 1:1000; Cell Signaling Technology); anti-vinculin
(SAB4200080, 1:5000; Sigma–Aldrich, St. Louis, MO), and
anti-b-actin (4967, 1:5000; Cell Signaling Technology).
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Secondary antibodies were anti-mouse HRP (#7076) and
anti-rabbit HRP (#7074), both from Cell Signaling Tech-
nology (1:5000).
Immunohistochemistry was performed on slices from
formalin-fixed paraffin-embedded thyroid tissues, as pre-
viously described (27), using primary antibodies against 4-
hydroxynonenal (4-HNE; ab46545, 1:350; Abcam, Cambridge,
United Kingdom) and cleaved caspase-3 (Asp175; 9661, 1:200;
Cell Signaling Technology). Specific binding was detected with
the Envision kit (Dako), and the color reaction was visualized
with 3,3¢-diaminobenzidine. For negative controls, blocking
solution was added instead of primary antibody.
Protein oxidation in thyroid tissue extracts was evaluated
by assaying the amount of carbonyl groups on proteins
from pooled samples of each experimental group using the
OxyBlot Protein Oxidation Detection kit (S7150; Merck
Millipore, Billerica, MA) following the manufacturer’s
protocol. Briefly, 10 lg of protein samples were derivatized
with 2,4-dinitrophenylhydrazine, and samples were loaded
onto a 6% or 10% SDS-PAGE. Western immunoblotting
was performed, as described above, using a specific anti-
body provided in the kit.
Cell culture
PCCL3 cells, a clonal rat thyroid cell line (30) were cul-
tured in Coon’s modified Ham’s F-12 medium supplemented
with 5% fetal bovine serum (FBS), 1% streptomycin/penicillin,
and a six-hormone (6H) mixture comprising 0.5mIU/mL of
TSH, 10 lg/mL of insulin, 5 lg/mL of human Apo trans-
ferrin, 10 nM of hydrocortisone, 10 ng/mL of somatostatin,
and 10 ng/mL of glycyl-L-histidyl-L-lysine acetate, here-
after referred to as 6H complete medium (30). Cells were
cultured at 37C, 5% CO2, in a humidified incubator. Cul-
ture media and supplements were all from Sigma–Aldrich.
The starvation medium, hereafter referred to as 4H medium,
contained 0.2% FBS and four of the six hormones from the
6H medium (it lacked TSH and insulin). HeLa cells were
cultured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% (v/v) fetal calf serum.
Cell treatments
Unless otherwise stated, all chemicals were from
Sigma–Aldrich. The following compounds were used for
cell treatments: sulforaphane (SLF; R-1-isothiocyanato-4-
methylsulfinylbutane) and CDDO-imidazole (CDDO-Im; 1-
[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole) are
Nrf2 activators; the latter was a gift from Prof. M. Sporn (Geisel
School ofMedicine,Dartmouth,NH) (31). Brusatol, an inhibitor
of Nrf2 signaling, was a gift from Prof. D. Zhang (University
of Arizona, Tucson, AZ) (32). OS conditions were induced
using H2O2 or glucose oxidase (GOx); the latter generates
H2O2 in the culture medium of the cells. NaI and the iodolipid
2-iodohexadecanal (2-IHDA) (33) were used to study the ef-
fects of iodide and its metabolites in cells.
Generation of stable ARE-Luc PCCL3 cell lines
A luciferase reporter plasmid (pNqo1-ARE-luc) bearing
the ARE present in the 5¢-flanking region of the rat quinone
reductase gene (34,35) was used to create a stable PCCL3-
ARE reporter cell line. PCCL3 cells plated into six-well
plates 24 hours earlier were transfected with pNqo1-ARE-luc
(500 ng), along with a pcDNA3.1 (50 ng) plasmid containing
the neomycin selectable marker (Invitrogen) using a com-
mercial transfection kit (jetPrime; Polyplus, Illkirch, France).
Cells were split into 96-well plates 48 hours later and then
selected using 500lg/mL of G418 (Invitrogen) in the me-
dium for three weeks. Resistant clones were isolated and
screened by measuring their basal and inducible (obtained by
treatment with 5lM of sulforaphane; Enzo Life Sciences,
Inc., Lausen, Switzerland) luciferase activities using the
Luciferase Assay System (Promega, Madison, WI). A clone
that displayed low background and high inducible luciferase
activity was passaged and used in downstream experiments.
Promoter analysis and Tg promoter reporters
The promoter sequences for human and mouse Tg were
downloaded from the EPDnew database (http://epd.vital-it.
ch) (36) (Promoter ID: TG_1) and the rat promoter from
NCBI GenBANK database (RefSeq: NC_005106.4). The
JASPAR core database (http://jaspar.genereg.net) (37) was
used to identify potential Nrf2 binding sites (ARE weight
matrix, MA0150.2; relative score 0.80) in a 3.5 kb region
upstream from the translation start site of the Tg gene. The
previously described luciferase reporter vector hTGenh/prm-
Luc (38) containing the human Tg upstream enhancer (39)
and proximal basic Tg promoter (40) cloned upstream of the
luciferase reporter gene of the PGL3 vector (hereafter, pTg)
were used. The AREs were mutagenized, each one individ-
ually (pTg_mut_ARE1, pTg_mut_ARE2), as well as both
together (pTg_mut_ARE1/2). The presence of ARE se-
quences in the enhancer region of the Tg promoter was
confirmed by Sanger sequencing. The pTg vector was used
as a template to create mutant versions of the core ARE
sequences, named pTg_mut_ARE1 and pTg_mut_ARE2.
Mutations were generated using the QuikChange II Site-
Directed Mutagenesis Kit (Stratagene, San Diego, CA)
following the manufacturer’s protocol. After verification by
Sanger sequencing, pTg_mut_ARE1 was used as a template
to create the double mutant vector pTg_mut_ARE1/2. Pri-
mers used for mutagenesis and sequencing are listed in
Supplementary Table S6.
RNA interference
Silencing of Nrf2 and Keap1was performed using siRNAs
from Santa Cruz Biotechnology (sc-156128 and sc-270459,
respectively). The non-targeting negative control siRNA (sc-
37007) was tested in parallel. PCCL3 cells were transfected
either under starvation conditions (4H medium for 5 days) or
under complete (6H) medium at a final siRNA concentration
of 20 nM using Lipofectamine RNAiMax (Invitrogen).
Compound treatments were performed 24 hours later, and
cells were collected 48 hours after the siRNA transfections.
Chromatin immunoprecipitation
Cells grown in 15 cm dishes in complete 6H medium for
48 hours (after initial plating of four million cells) were treated
with 5lM of SLF or 0.1% dimethyl sulfoxide vehicle. Fol-
lowing 24 hours of treatment, cells were used for chromatin
immunoprecipitation (ChIP) assays using the HighCell ChIP
kit (Diagenode, Liege, Belgium) following the manufacturer’s
Nrf2 REGULATES ROS AND THYROGLOBULIN IN THYROID 783
D
ow
nl
oa
de
d 
by
 1
68
.9
6.
24
0.
2 
fro
m
 w
w
w
.li
eb
er
tp
ub
.co
m
 at
 0
2/
05
/2
0.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
instructions. A 1% portion of sheared cross-linked chromatin
from each experimental condition was saved to serve as input
DNA, and the rest was divided into equal parts and im-
munoprecipitated overnight at 4Cusing 4lgof rabbit-anti-Nrf2
polyclonal antibody (sc-13032 X; Santa Cruz Biotechnology)
or 4lg of rabbit IgG provided in the kit. Immunoprecipitated
DNA were quantified by real-time RT-PCR using a standard
curve from serial dilutions of input DNA and the primer pairs
listed in Supplementary Table S7: (i) flanking the ARE1 se-
quence in the rat Tg promoter; (ii) flankingARE2; (iii) flanking
a validated ARE (positive control) in the rat Nqo1 promoter
(34); or (iv) targeting an unrelated sequence (negative control)
about 350 bp downstream of the 5¢ end of the Actb gene.
Quantified DNA for each target was normalized to corre-
sponding input DNA, and the results were plotted as fold
enrichment of the target sequence versus the negative control.
Generation of PCCL3-ARE Nrf2 KO or Keap1
KO cells using CRISPR/Cas9
The PCCL3-ARE cells were used to inactivate the ex-
pression of Nrf2 or Keap1 using the CRISP/Cas9-mediated
gene editing technology (41) and, specifically, the Edit-R
gene editing system (Dharmacon, Inc., Lafayette, CO). Three
different crRNAs (Supplementary Table S8) were tested for
each target. Briefly, PCCL3-ARE cells grown in 12-well
plates without antibiotics were transfected with 0.5 lg of
Edit-R Cas9 expression plasmid (U-005100; Dharmacon,
Inc.) using jetPrime transfection reagent. Twenty-four hours
later, cells in each well were transfected again with a 10 pmol
mixture of crRNA:tracrRNA complex (10 nM final concen-
tration) and 1.7 lL of lipofectamine RNAiMAX in Optimem
medium preincubated for 20min at room temperature. Cells
were trypsinized 48 h later and plated into six-well plates
under puromycin selection for three more days. Surviving
cells were split into 96-well plates (100 cells/plate) without
puromycin, and single colonies were selected three weeks
later. For Nrf2 targeting, colonies were screened by mea-
suring their basal and inducible (obtained by treatment with
5 lM of SLF) ARE-dependent luciferase activities. Colonies
with very low background and with no response to SLF
treatment were selected. For Keap1 targeting, colonies were
screened by measuring their basal luciferase activities. Co-
lonies with at least threefold higher activity over the parental
PCCL3-ARE cells were selected. Detection of frameshift
mutations in the selected colonies was performed with Sanger
sequencing on PCR-amplified DNA using primers flanking
the target DNA sequence of each specific guide RNA
(primers in Supplementary Table S9). Colonies with biallelic
mutations (frameshift-causing single-base deletions of the
target sequence) were selected. HomozygousNrf2KO clones
were named N2 and N3, and homozygous Keap1 KO clones
were named K1 and K3. A colony originating from an Nrf2-
targeting crRNA that did not yield a mutation was used as a
control in downstream experiments (originally N1, then re-
labeled WT).
Cell transfections and reporter assays
Transient transfections of cells with the different pTg re-
porters were performed in 96-well plates cultured in com-
plete medium using a 1:2 ratio of DNA and jetPRIME
transfection reagent, respectively. The pEGFP-N1 plasmid
(Clontech, Mountain View, CA) was included for monitoring
transfection efficiency, along with the Renilla pRLTK-
DARE plasmid to normalize luciferase activities, as previ-
ously described (42).When the Nrf2-activating compounds
SLF and CDDO-Im were used, they were applied 24 hours
after transfection for the indicated times. In all transfections,
the pEGFP-N1 plasmid (Clontech) was included for moni-
toring transfection efficiency 24 hours after transfection by
examining cells under an Eclipse TS100 inverted fluores-
cence microscope (Nikon, Tokyo, Japan). Transfection effi-
ciency was determined by the percentage of green fluorescent
cells in the whole cell population. Experiments were per-
formed only if transfection efficiency was the same between
the different conditions. The Renilla pRLTK-DARE plasmid
was used to normalize luciferase activities, as previously
described (42). Cells were lysed 48 hours after transfection
using Passive Lysis Buffer (Promega). The dual luciferase
reporter assay (Promega) and a NOVOstar luminometer
(BMG Labtech, Ortenberg, Germany) were used to measure
luciferase activities according to the manufacturer’s protocol.
PCCL3 cells were transfected with 50 ng of total plasmid
DNA per well as follows: 40 of WT pTg or the same quantity
of indicated pTg_mut_ARE, 2 ng of pEGFP-N1, and 8 ng of
pRLTK-DARE. HeLa cells were transfected with 35 ng of
total plasmid DNA per well as follows: 12 of WT pTg or the
same quantity of indicated pTg_mut_ARE, 0.5 ng of pEGFP-
N1, 2.5 ng of pRLTK-DARE, 10 ng of pCDNA-Ttf1 (a gift
from Prof. D. Mu (Eastern Virginia Medical School, Norfolk,
VA), addgene plasmid #49989) (43), and 10 ng of pCDNA-
Nrf2, pCDNA-Keap1, or pCDNA-mock (the latter three
plasmids were kindly provided by Dr. N. Wakabayashi
[University of Pittsburgh, Pittsburgh, PA]) (42).
General reactive oxygen species detection
The detection of endogenous reactive oxygen species
(ROS) production was evaluated using the fluorescent probe
CM-H2DCFDA (Thermo Fisher Scientific). Briefly, cells
were washed with Hank’s balanced salt solution (HBSS) and
incubated with 5lM of CM-H2DCFDA, along with 1 lM of
Hoechst 33342 (Thermo Fisher Scientific) for 20min at
37C. Cell were then washed again with HBSS and allowed
to recover for another 30min at 37C. Fluorescence was
observed under an Eclipse TS100 microscope, and images
were captured using a Digital Sight camera (Nikon).
Statistics
Results are presented in graphs as means – standard devi-
ation. Hormone levels were compared by two-way analysis
of variance between WT and Nrf2 KO mice treated with NaI
or not, testing for main effects (genotype, treatment), and
interaction effects (genotype–treatment). Hormone levels
were compared by unpaired t-test between WT and ts-KO
mice. These statistical calculations were performed in
GraphPad Prism v7 (GraphPad Software, Inc., La Jolla, CA),
which was also used to prepare all graphs. For data cal-
culated as normalized ratios (mRNA, protein, and lucifer-
ase quantifications), the BootstRatio application was used
(http://rht.iconcologia.net/stats/br/index.html). This tool is
based on bootstraping and resampling methods, without
any assumption on the underlying probability distribution
for the data analyzed (44). Whenever the same data were
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used to test multiple hypotheses, a Bonferroni correction
was applied as appropriate.
Results
Ubiquitous Nrf2 KO mice demonstrate that Nrf2
mediates protective antioxidant responses
to iodide overload and impacts Tg expression
and iodination levels
Under normal conditions, Nrf2 KO mice showed similar
TSH levels as WT mice, indicating a euthyroid state
(Fig. 1A). In both genotypes, TSH levels increased signifi-
cantly and to a similar extent after iodide overload for one
week (Fig. 1A). Genotype, treatment, and their interaction
had no significant impact on total T3 levels (Fig. 1B). Total
T4 levels, which decreased significantly in both genotypes in
response to iodide, were slightly higher in the Nrf2 KO mice
compared to WT mice both under basal conditions and after
iodide overload (Fig. 1C). This was confirmed in an inde-
pendent cohort of animals (Fig. 1D). The genotype–treatment
interaction did not show a significant effect for any of the
three hormones. Together, these data indicate that Nrf2 KO
mice show, compared to WT mice, only minor differences in
thyroid function tests under basal conditions, notably in total
T4 levels. The absolute magnitude of these differences is
small, and they are not accompanied by a significant differ-
ence in TSH levels, indicating normal overall thyroid func-
tion. Moreover, the physiological hormonal response to
excess iodide is largely preserved in Nrf2 KO mice under the
conditions employed.
The study validated that Nrf2 KOmice show no expression
of Nrf2 in their thyroid glands, and found that iodide overload
had no effect on Nrf2 mRNA levels in WT mice (Fig. 1E).
Expression levels of the prototypical Nrf2 target gene, Nqo1,
were significantly lower in Nrf2 KO mice compared to WT
mice both under basal conditions and after iodide challenge
(Fig. 1F). Moreover, Nqo1 mRNA levels were significantly
upregulated by iodide treatment in WT mice, while no in-
duction was observed in KO mice (Fig. 1F), indicating that
iodide activates the Nrf2 antioxidant response in the thyroid
gland. The mRNA levels of Gpx2 (Fig. 1G) showed the same
statistically significant patterns as Nqo1, indicating that this
gene is also upregulated by iodide in a Nrf2-dependent
manner. A similar but not statistically significant pattern was
observed for Txnrd1 mRNA levels (Fig. 1H). Under both
basal and iodide overload conditions, Tg mRNA levels were
markedly lower in Nrf2 KO mice compared to WT (Fig. 1I).
As expected (45), Nis mRNA levels were significantly re-
duced in response to iodide in WT mice. This response was
preserved in Nrf2 KO mice (Fig. 1J). A trend toward lower
Nis mRNA levels was observed in Nrf2 KO mice compared
toWT, which was statistically significant under iodide overload
conditions (Fig. 1J). The expression levels of other thyroid-
specific genes are shown in Supplementary Figure S1A–J.
Overall, these data demonstrate that Nrf2 mediates thyroidal
antioxidant responses to iodide and that it has a major impact on
TgmRNA levels independently of iodide. Thus, subsequent
investigations were focused on elucidating the mechanisms
involved.
At the protein level, Nqo1was detectable only in WTmice
exposed to iodide, while it was undetectable under basal
conditions in WT mice, as well as in Nrf2 KO mice in either
condition (Fig. 1K and Supplementary Fig. S2). This pattern
is consistent with the respective mRNA expression levels
(Fig. 1F). When the total oxidized protein content was as-
sayed,WTmice showed amild decrease in response to iodide
overload (Fig. 1L). This is compatible with a known auto-
regulatory response whereby H2O2 levels decrease in re-
sponse to high iodide (46). On the other hand, Nrf2 KO mice
showed a mild increase in total protein oxidation under basal
conditions, as well as a clear increase after iodide challenge
(Fig. 1L), suggesting a dysfunction in this autoregulatory
mechanism. Challenging Nrf2 KO mice with iodide also
caused a clear increase in immunostaining for the oxidized
lipid product 4-HNE in thyroid follicular cells (Fig. 1M).
Together, these data indicate that the Nrf2-mediated anti-
oxidant response protects the thyroid gland from iodide
overload-induced oxidative damage. Overall, no major gross
morphological abnormalities were observed among the
groups, but a detailed histomorphological characterization of
the thyroids of Nrf2-KO mice (and other Nrf2-KO vertebrate
models) is in progress. Immunohistochemistry for cleaved
caspase 3 showed very low levels of apoptosis in WT mice
under normal conditions, as well as in the various experi-
mental groups (Supplementary Fig. S3). The number of fol-
licles that harbored at least one cleaved caspase 3-positive
cell ranged from 0% to 1% in all groups.
Consistent with the pattern of Tg mRNA levels (Fig. 1I),
Tg protein levels were significantly lower in Nrf2 KO mice
compared to WT mice, both under basal conditions (Fig. 2A,
C, D, F, and P) and in response to iodide challenge (Fig. 2B,
C, E, F, and T). On the contrary, iodinated Tg (I-Tg) levels
were significantly higher in Nrf2 KO mice compared to WT
mice under basal conditions (Fig. 2G, I, Q, and R). Moreover,
whereas I-Tg levels decreased in WT mice in response to
iodide overload, they increased significantly in Nrf2 KOmice
(Fig. 2G–I, U, and V). These data suggest that the iodide
overload-induced inhibition of Tg iodination (the Wolff–
Chaikoff phenomenon) (47) is dysfunctional in Nrf2 KO
mice. On the other hand, NIS protein levels appropriately
decreased in both WT and Nrf2 KO mice (Fig. 2J–L, S, and
W), indicating that the escape mechanism from the Wolff–
Chaikoff phenomenon (45) is not dependent on Nrf2. Taken
together, these data show clear effects of Nrf2 on the protein
levels of Tg and its iodinated form, indicating partial dys-
function of the iodide-handling mechanisms in thyrocytes.
The main results of the above-described mouse experiments
among the different genotypes and conditions are summa-
rized in Table 1.
Thyroid-specific Nrf2 KO mice show that
the effects of Nrf2 on antioxidant genes
and Tg are thyroid autonomous
To distinguish which of the aforementioned effects of Nrf2
are thyroid autonomous and which are mediated by actions of
Nrf2 in peripheral tissues, thyroid-specific (ts-)Nrf2 KOmice
(Pax8-Cre/+, Nrf2 flox/flox) were generated, and they were
compared to littermate control Nrf2 flox/flox mice under
basal conditions. The levels of plasma TSH, total T4, and
total T3 were similar between the two genotypes (Fig. 3A–C),
indicating that the observed difference in total T4 levels be-
tween ubiquitous Nrf2 KO and WT mice (Fig. 1C and D) is
likely due to extrathyroidal effects of Nrf2 on the transport or
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FIG. 1. Thyroid function tests, relative thyroidal gene expression levels, thyroidal Nqo1 protein levels, and thyroidal
oxidized protein levels of wild-type (WT) and NFE2-related transcription factor 2 (Nrf2) knockout (KO) male mice under
basal conditions and after iodide overload. Three- to four-month-old male mice were supplied for seven days with normal
water (-C) or with 0.05% sodium iodide (NaI) in their drinking water (-I). (A) Plasma thyrotropin (TSH), (B) total
triiodothyronine (T3), and (C) total thyroxine (T4) were measured by radioimmunoassay (RIA) in WT-C, WT-I, KO-C, and
KO-I mice (seven mice per group). (D) Plasma total T4 was measured by enzyme-linked immunosorbent assay in an
independent cohort of animals (10 mice per group). (E) Nrf2 (F) Nqo1 (G) Gpx2 (H) Txnrd1 (I) Tg, and (J) Nis mRNA
levels were quantified by real-time reverse transcription polymerase chain reaction (RT-PCR) in WT-C (n = 9), WT-I
(n = 12), KO-C (n = 10), and KO-I (n = 10) mice. Results for each mouse are presented as relative quantity over the mean of
the WT-C group. Error bars indicate means – standard deviation. *p < 0.05 vs. WT-C; xp< 0.05 vs. KO-C; #p < 0.05 vs. WT-
I. (K) Nqo1 protein levels were assayed by Western immunoblotting in thyroid protein extracts from WT-C, WT-I, KO-C,
and KO-I mice (seven mice per group). A pooled sample from each group was run in duplicate (two lanes per group). As
controls for protein loading, the membranes were stripped and re-probed with an anti-actin antibody and then also stained
with Coomassie blue. (L) As an index of oxidative stress, protein carbonyl content was assayed using the OxyBlot Protein
Oxidation Detection kit. Pooled protein thyroid extracts from the same animals were treated accordingly then separated
on a 6% or a 10% gel, and detection of carbonyl protein modifications was performed by Western immunoblotting. The
membranes were stripped and re-probed with an anti-actin antibody and then also stained with Coomassie blue. Den-
sitometric quantification of relative protein carbonyls in the different groups was performed using Image-J software. The
graph shows relative band intensity normalized to the corresponding actin band and to the WT-C group. (M) Im-
munohistochemical staining for 4-HNE in representative thyroid slices each group. Arrows indicate positive control
staining in fat tissue.
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peripheral metabolism of T4. The mean Nrf2 mRNA levels
in the ts-Nrf2 KO mice were 7.5% of WT levels (range 4.9–
10%; Fig. 3D). Given that the thyroids of these animals
also contain cells that are WT for Nrf2 (e.g., endothelial
cells, blood cells, fibroblasts, adipocytes, etc.), it was con-
cluded that the efficiency of the knockout is >90%. Im-
portantly, these mice recapitulated the differences observed
in ubiquitous Nrf2 KOmice in the basal expression levels of
antioxidant genes (Fig. 1F–H), showing significantly lower
mRNA levels of Nqo1 (Fig. 3E) and Gpx2 (Fig. 3F) as well
as of Txnrd1 (Fig. 3G). Similarly to ubiquitous Nrf2 KO
mice (Fig. 1I), they also showed markedly lower mRNA
FIG. 2. Thyroglobulin (Tg), iodinated Tg (I-Tg), and NIS protein levels in thyroids of WT and Nrf2 KO male mice under
basal conditions and after iodide overload. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and
Coomassie blue staining of thyroid protein extracts from individual animals (WT-C, KO-C, WT-I, and KO-I; seven mice per
group) under basal conditions (A) or after iodide treatment (B) and in respective pooled extracts (C). Western immuno-
blotting for Tg (D, E, and F), I-Tg (G, H, and I), NIS (J, K, and L), and actin (M, N, and O). Lad indicates protein ladder
size marker. (P–W) Densitometric quantification of relative protein levels in the different mice was performed using Image-
J, with normalization to the respective actin levels and to the appropriate control group (WT-C or WT-I). Error bars indicate
means – standard deviation. *p < 0.05.
Table 1. Summary of the Main Findings in Mice
WT-I
Nrf2
KO-C
Nrf2
KO-I
Tg mRNA – Y Y
Tg protein Y Y Y
Iodinated Tg Y [ [[
Nqo1 (Gpx2, Txrnd1) mRNA [ Y Y
Oxidized proteins – – [
Oxidized lipids – – [
Arrows indicate changes compared to WT-C mice; -, unchanged.
WT, wild type; KO, knockout; Tg, thyroglobulin.
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levels of Tg compared to controls (Fig. 3H). Nis mRNA
levels were also significantly lower (Fig. 3I), consistent
with the nonsignificant trend observed in ubiquitous
Nrf2 KO mice (Fig. 1J). Gene expression levels of other
thyroid-specific genes are shown in Supplementary
Figure S1K–T.
At the protein level, Tg was significantly less abundant in
the thyroids of ts-Nrf2 KOmice in basal conditions compared
to controls (Fig. 3J, K, and O). Conversely, the levels of
iodinated Tg were higher in ts-Nrf2 KOmice (Fig. 3L and P),
and the ratio of iodinated to total Tg was markedly higher
in ts-Nrf2 KO mice compared to controls (Fig. 3Q). Thus,
ts-Nrf2 KO mice under basal conditions recapitulate the
phenotype of ubiquitous Nrf2 KO mice regarding lower
mRNA expression of antioxidant genes, lower mRNA ex-
pression, and protein abundance of Tg, as well as higher
levels of Tg iodination, which indicates that these effects are
mediated via actions of Nrf2 in the thyroid gland.
FIG. 3. Thyroid function tests, relative thyroidal gene expression levels, and Tg, I-Tg, and NIS protein levels in control
(C, Nrf2 flox/flox) and thyroid-specific (ts-) Nrf2 KO male mice under basal conditions. Plasma TSH (A), total T3 (B), and
total T4 (C) were measured by RIA in three- to four-month-old C and ts-Nrf2 KO mice (seven mice per group). Nrf2 (D),
Nqo1 (E), Gpx2 (F), Txnrd1 (G), Tg (H), and Nis (I) mRNA levels were quantified by real-time RT-PCR. Results for each
mouse are presented as relative quantity over the mean of the C group. (J) SDS-PAGE and Coomassie blue staining of
thyroid protein extracts from individual animals. Western immunoblotting for Tg (K), I-Tg (L), NIS (M), and actin (N). Lad
indicates protein ladder size marker. (O–R) Densitometric quantification of relative protein levels in the different mice was
performed using Image-J, with normalization to the respective actin levels and to the C group. Error bars indicate
means – standard deviation. *p < 0.05.
788 ZIROS ET AL.
D
ow
nl
oa
de
d 
by
 1
68
.9
6.
24
0.
2 
fro
m
 w
w
w
.li
eb
er
tp
ub
.co
m
 at
 0
2/
05
/2
0.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Nrf2 regulates antioxidant responses, as well
as the basal and TSH-inducible Tg levels,
in a cell-autonomous manner
To characterize further the thyroidal effects of Nrf2 on
antioxidant responses and Tg levels and to associate them
definitively with the thyroid follicular cells, first Nrf2 was
knocked down in the PCCL3 rat thyroid follicular cell line
using RNA interference. The efficiency of the knockdown
under the various conditions employed is shown in Supple-
mentary Figure S4A, B, G, and H. Knockdown of Nrf2 sig-
nificantly decreased the mRNA levels of Nqo1 under basal
conditions (Supplementary Fig. S4C), under starvation con-
ditions (Fig. 4A), and in response to TSH re-treatment
(Fig. 4A). Conversely, knockdown of Keap1 significantly
increased the mRNA levels of Nqo1 under basal conditions
(Supplementary Fig. S4C) and under starvation conditions
(Fig. 4A). Regarding Tg, knockdown of Keap1 clearly in-
creased its mRNA levels under basal conditions (Supple-
mentary Fig. S4D) and under starvation conditions (Fig. 4B),
while knockdown of Nrf2 significantly decreased Tg mRNA
levels in response to TSH stimulation (Fig. 4B) but not its
basal expression levels (Supplementary Fig. S4D), indicat-
ing that even low Nrf2 expression levels (Supplementary
Fig. S4A) can maintain physiological Tg expression. Having
verified that treatment of PCCL3 cells with pharmacological
activators of Nrf2 (CDDO-Im [CD for short] and SLF) sta-
bilizes Nrf2 and increases Tg protein levels in cells starved
in the presence of TSH or TSH plus insulin (Supplementary
Fig. S4K), it was found that the knockdown of Nrf2 clearly
decreased the inducible protein levels of Tg (Fig. 4C).
Conversely, the knockdown of Keap1 tended to increase
the inducible protein levels of Tg under the same conditions
(Fig. 4C).
Based on these findings under partial genetic loss- or gain-
of-function conditions, CRISPR/Cas9 gene editing was then
employed to generate PCCL3 rat cell lines KO for Nrf2
(named N2 and N3) or forKeap1 (named K1 and K3). Clones
were validated by Sanger sequencing genetically and also
functionally after pharmacological stimulation with SLF, as
it was found that SLF stabilized Nrf2 in WT cells but not in
Nrf2 KO cells. Conversely, Nrf2 was constitutively activated
FIG. 4. Small interfering RNA (siRNA)-mediated silencing or CRISPR/Cas9-mediated knockout of Nrf2 and Keap1 in
PCCL3 cells. (A–C) PCCL3 rat thyroid cells maintained for five days under starvation conditions (4H medium without TSH
and insulin) were transfected as indicated with siRNAs targeting Nrf2 or Keap1 or a non-targeting control oligonucleotide
(‘‘C’’). Cells were treated 24 hours later as indicated with 0.5mIU/mL of TSH or with TSH and 10 lg/mL of insulin (INS)
with or without sulforaphane (SLF) for another 24 hours. Relative mRNA levels of Nqo1 (A) and Tg (B) normalized to
Rpl19 as the reference gene were quantified by real-time RT-PCR. Error bars indicate means– standard deviation of at least
three independent experiments. *p < 0.05 vs. C; xp < 0.05 vs. C_TSH. (C) Western blot analysis of Tg, NIS, Nrf2, and
vinculin (Vin) as a loading control. (D–J) CRISP/Cas9-mediated gene editing was used to create stable PCCL3 cell clones
with targeted homozygous inactivation of Nrf2 (clones N2 and N3) or Keap1 (clones K1 and K3). (D) Western immu-
noblotting analysis of Nrf2 expression under basal conditions (complete culture medium) or after pharmacological Nrf2
activation with SLF (5lM) for 24 hours. The arrow indicates the specific Nrf2 protein band. WT denotes different cell
clones with no disruption of Nrf2 or Keap1, selected under the same conditions as the KO clones. Vin served as loading
control. (E) Western immunoblotting analysis of Tg and NIS abundance in WT and KO cell lines under basal conditions
(complete culture medium). Relative mRNA expression levels of Nqo1 (F), Gpx2 (G), Txnrd1 (H), Tg (I), and Nis (J)
normalized to Rpl19 as the reference gene were quantified by real-time RT-PCR in cells cultured as above. Error bars
indicate means – standard deviation of at least three independent experiments. *p < 0.05 vs. WT.
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in Keap1 KO cells (Fig. 4D). Under basal conditions, Tg
mRNA and protein levels were markedly lower in Nrf2 KO
cells and higher in Keap1 KO cells (Fig. 4E and I). The same
pattern was observed in the mRNA expression levels of an-
tioxidant genes (Fig. 4F–H), with lower basal levels of Nqo1,
Gpx2, and Txnrd1 mRNA in Nrf2 KO cells and higher levels
in Keap1 KO cells.Nis showed a non-significant tendency for
lower mRNA levels in Nrf2 KO cells (Fig. 4J). Expression
levels of other thyroidal genes are shown in Supplementary
Fig. S4L–Q. Compared to the differences in Tg levels, in
those cases when differences in other thyroidal genes were
observed, they were of small magnitude, inconsistent be-
tween the two lines of the same genotype, and/or similar
between Nrf2 KO cells and Keap1 KO cells, suggesting that
among thyroid-specific genes, only Tg was likely to be under
direct regulation by Keap1/Nrf2 signaling.
Then, the same parameters were assayed in response to
starvation followed by stimulation by either TSH or TSH plus
insulin. Tg protein levels were undetectable after starvation
inWT cells (Fig. 5A). This has been previously described and
is considered a result of a general quiescence of the cells in
the absence of TSH and insulin/IGF-1 signaling (48,49). In
WT cells, TSH re-treatment induced detectable levels of Tg.
In contrast, stimulated Tg was hardly detectable in TSH-re-
treated Nrf2 KO cells (Fig. 5A). Conversely, high levels of
Tg were detectable in Keap1 KO cells under starvation
conditions, with further induction upon TSH re-treatment
(Fig. 5A). Similar differences were observed when starved
cells were treated with both TSH and insulin (Fig. 5B), the
latter being known to yield a more potent induction of Tg
compared to TSH treatment alone (48). The differences in
inducible Tg levels observed after 24 hours of treatment also
persisted after a more prolonged stimulation of the cells for
48 hours (Supplementary Fig. S5A). Of note, the patterns of
Tg expression in the cell culture media matched very well
the patterns of the respective cellular extracts, suggesting that
the differences observed between genotypes were not due to
altered export of Tg (Supplementary Fig. S6). Moreover,
overexposure of the blots from cell extracts did not reveal
more Tg bands of lower molecular weight in the Nrf2 KO
cells. This would argue against excessive Tg degradation in
these cells (Supplementary Fig. S6). Similarly, overexpo-
sure of the blots from mouse thyroid extracts did not reveal
more Tg bands of lower molecular weight in the ts-Nrf2 KO
mice compared to control mice (Supplementary Fig. S7),
arguing against increased Tg degradation in vivo as well.
Finally, Western immunoblotting for various markers of
endothelial reticulum stress (BIP, pERK, and pJNK) or
autophagy (Beclin, ATG12-ATG5, and Lc3b) did not
suggest differences in the activation status of these stress
pathways between WT cells, Nrf2 KO cells and Keap1 KO
cells (Supplementary Fig. S8).
Consistent with the Tg protein expression patterns, both
the basal and the inducible Tg mRNA levels were also
markedly lower in Nrf2 KO cells and higher in Keap1 KO
cells (Fig. 5C). Interestingly, TSH- or TSH and insulin-
inducible Nis mRNA and protein levels were lower in
Keap1 KO cells (Fig. 5A and D) compared to WT cells. The
expression patterns of other thyroidal genes are shown in
Supplementary Figure S5B–N. The mRNA expression
patterns of antioxidant genes (Nqo1, Gpx2, and Txnrd1) are
consistent with regulation by the Keap1/Nrf2 pathway
FIG. 5. Impact of Nrf2 or Keap1 knockout on TSH-
inducible thyroid-specific protein and gene expression in
PCCL3 cells. PCCL3 WT or KO cells maintained for five
days under starvation conditions (4H medium without TSH
and insulin) were stimulated with 0.5mIU/mL of TSH (A)
or 0.5mIU/mL of TSH and 10 lg/mL of insulin (B) for
24 hours. (A and B) Western immunoblotting for Tg, NIS,
and Vin as a loading control was performed using total
protein extracts from the above conditions. The asterisk (*)
indicates intentional overexposure of the Tg immunoblot
to visualize the faint bands in the Nrf2 KO clones. Relative
mRNA levels of Tg (C) and Nis (D) normalized to the
Rpl19 reference gene were quantified by real-time RT-PCR.
T, TSH; INS, insulin. Error bars indicate means– standard
deviation of at least three independent experiments. *p< 0.05
vs. WT; xp< 0.05 vs. WT_T; #p< 0.05 vs. WT_T + INS.
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under TSH and/or TSH and insulin stimulation conditions
(Supplementary Fig. S5B–D). In conclusion, these data
demonstrate that the Keap1/Nrf2 pathway has an impact on
the expression levels of antioxidant genes, as well as on the
basal and inducible levels of Tg in thyroid follicular cells.
Given the known functions of Nrf2 in other tissues, regu-
lation of antioxidant genes in the thyroid was highly plau-
sible. Yet, the relationship with iodide warranted further
investigation. Moreover, regulation of Tg, a tissue-specific
protein, by a ubiquitous transcription factor like Nrf2 was a
highly intriguing finding, prompting the underlying mech-
anisms to be elucidated.
Iodide and its active metabolite 2-IHDA regulate
ARE-mediated transcription in thyroid follicular cells
To investigate mechanisms of transcriptional regulation by
Nrf2, PCCL3 cells stably transfected with an ARE-luciferase
reporter construct (PCCL3-ARE cells) were employed. Pre-
liminary experiments verified that this reporter responded in
a dose-dependent manner to treatment with pro-oxidant
substances such as glucose oxidase (GOx) and H2O2 (Sup-
plementary Fig. S9A) or with the Nrf2 activator CDDO-Im
(Supplementary Fig. S9C). Moreover, the Nrf2 inhibitor
brusatol decreased the basal, H2O2-inducible, and CDDO-
Im-inducible reporter activity in a dose-dependent manner
(Supplementary Fig. S9B and D). Reporter activity was also
significantly induced by treatment with TSH and insulin,
whereas it was slightly suppressed by TSH alone (Supple-
mentary Fig. S9E).
When WT PCCL3-ARE cells were treated with iodide,
reporter activity increased significantly. This induction was
completely blocked by concurrent treatment with the free
radical scavenger NAC, which also reduced significantly the
basal reporter activity (Fig. 6A). In contrast, neither iodide
nor NAC had any effect on reporter activity in Nrf2 KO
PCCL3-ARE cells. Also, in these cells, the basal ARE ac-
tivity was significantly reduced compared to WT PCCL3-
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FIG. 6. Effects of iodide and
2-iodohexadecanal
(2-IHDA) on Nrf2-mediated
ARE activity and target gene
transcription. Equal numbers of
PCCL3 ARE-WT or ARE-
Nrf2-KO cells cultured in
complete medium in 24-well
plates were treated for 36 hours
at 70% confluency with the
following compounds: (A)
1mM of NaI (‘‘I’’) or 1mM of
the free radical scavenger N-
acetylcysteine (NAC), or both;
control wells (‘‘C’’) were trea-
ted only with vehicle
(water). (B) 20lM of 2-
iodohexadecanal or 2 or 5lM
of SLF for 24 hours. Luciferase
reporter activity was
determined in cell extracts from
the respective conditions. Re-
sults are presented as fold ac-
tivity over the respective
control group treated with
vehicle only. (C–F) PCCL3
ARE-WT or ARE-Nrf2-KO
cells were treated as above and
relative mRNA levels of Tg
(C), Nqo1 (D), Gpx2 (E), and
Txnrd1 (F) normalized to
Rpl19 as the reference gene
were quantified by real-time
RT-PCR. Error bars indicate
means– standard deviation
of at least three independent
experiments. *p< 0.05 vs. WT-
C; #p< 0.05 vs. respective
treated WT; n.s., not
significant.
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ARE cells (Fig. 6A). These data suggest that iodide exposure
activates Nrf2 signaling in a ROS-dependent manner. This
was further confirmed by assaying overall ROS levels using
the fluorescent probe CM-H2DCFDA in WT, Nrf2 KO, and
Keap1 KO PCCL3 cells treated with iodide with or without
NAC (Supplementary Fig. S10). In addition, basal ROS
levels were higher in Nrf2 KO cells and lower in Keap1 KO
cells (Supplementary Fig. S10).
The effects of iodide in thyroid follicular cells are believed
to be exerted mainly by iodide metabolites produced via
oxidative reactions with cellular lipids. One of the main ac-
tive iodide intermediates is 2-IHDA (50). Thus, cells were
treated with 2-IHDA (or SLF as a positive control) and ARE
activity and mRNA expression levels of antioxidant genes
and of Tg were assayed. Both SLF and 2-IHDA activated the
ARE in WT cells (Fig. 6B). In Nrf2 KO cells, basal ARE
activity was markedly reduced and inducibility by SLF, and
2-IHDAwas abolished (Fig. 6B). The exact same pattern was
observed in the mRNA levels of Tg (Fig. 6C). Similar pat-
terns were also observed in the mRNA levels of antioxidant
genes, with some specificities among them. For example,
basal levels were reduced in Nrf2 KO cells for Nqo1 and
Gpx2 (Fig. 6D and E) but not for Txnrd1 (Fig. 6F). In all
cases, inducibility by SLF and 2-IHDAwas abolished in Nrf2
KO cells (Fig. 6B–F). Taken together, these data indicate that
iodide and its active intermediate 2-IHDA can activate Nrf2
signaling in thyroid follicular cells and that Nrf2 activation
by iodide is mediated by ROS.
Nrf2 directly controls Tg gene expression
via binding to two functional AREs
in a conserved upstream enhancer
Since the aforementioned data indicated transcriptional
regulation of the Tg gene by Nrf2, the study sought to clarify
the underlying mechanism. Thus, the known regulatory se-
quences of the human TG gene were analyzed, namely a
proximal promoter and a distal upstream enhancer (38), for
potential Nrf2 binding sites. While the proximal promoter
did not contain any potential AREs, two such sequences
(ARE1 and ARE2) were identified in the upstream enhancer
(Fig. 7A): ARE1 lies on the forward DNA strand between
-2830 and -2816 bp from the transcription start site (TSS),
and ARE2 lies on the reverse strand between -3229 and
-3215 bp. This human enhancer sequence is known to con-
tain functional binding sites for thyroid transcription factor-1
(TTF1; NKX2.1), and it has been described in the human and
bovine genes (39,51), but it has not been reported whether it
is conserved in rodents. The sequence alignments showed
that this enhancer sequence is conserved between humans,
mice, and rats (Fig. 7A). Interestingly, among the known and
putative regulatory elements identified, only one of the three
TTF1 binding sites is conserved among these species, while a
previously described putative adenosine 3¢,5¢-cyclic mono-
phosphate response element–like element (52) is not con-
served in rodents. In contrast, both ARE elements were also
identified in the Tg promoter of the rat (rARE1 from -2414
to -2400, and rARE2 from -2750 to -2736) and mouse
(mARE1 from -2384 to -2316, and mARE2 from -2712 to
-2698). These two AREs are thus located at about the same
distance from the corresponding TSS in the studied species,
have a similar distance between them, and display the same
orientation regarding their location on the forward (ARE1) or
reverse (ARE2) DNA strand (Fig. 7A).
To test whether the predicted AREs are functional, a pre-
viously described human TG enhancer-promoter luciferase
reporter construct was employed (38). First, it was shown that
reporter activity is induced by treatment with SLF or CDDO-
Im (Supplementary Fig. S11A). Next, ARE1, ARE2, or both
were mutagenized in the reporter construct, introducing
mutations predicted to abolish Nrf2 binding, and then tran-
sient transfection experiments were performed in PCCL3
cells. In WT cells, mutation of either ARE1 or ARE2 sig-
nificantly reduced both the basal and the SLF-inducible re-
porter activity (Fig. 7B). Moreover, the mutation of both
AREs further reduced basal reporter activity and completely
abolished its inducibility by SLF (Fig. 7B). In a heterologous
system (Hela cells transfected with TTF1), WT reporter ac-
tivity was increased by SLF treatment, co-transfection of
Nrf2, or their combination, whereas it was reduced by co-
transfection of Keap1. The ARE1/2 double mutant reporter
showed no response under these conditions (Supplementary
Fig. S11B). Taken together, these data indicate that both
AREs in the upstream Tg enhancer are transcriptionally
functional. The study therefore tested for direct binding of
Nrf2 to these sequences by ChIP in WT and Nrf2 KO PCCL3
cells (Fig. 7C). In WT cells, a significant enrichment of Nrf2
binding over a negative control was evident under basal
conditions for both AREs, comparable to binding to a known
functional ARE in the Nqo1 gene. For both AREs, Nrf2
binding increased significantly in response to SLF treatment
in WT cells. In contrast, in Nrf2 KO cells, only a background
signal was detected for both AREs either under basal con-
ditions or in response to SLF, similar to the control Nqo1
ARE (Fig. 7C). Taken together, these data demonstrate that
Nrf2 can directly upregulate Tg gene expression via binding
to two functional AREs in a conserved upstream enhancer.
The main results of the above-described cell culture experi-
ments among the different genotypes and conditions are
summarized in Table 2.
Discussion
The present findings show that Nrf2 exerts pleiotropic
functions in the thyroid gland (Tables 1 and 2 and Fig. 8). For
some of these roles, in large part the underlying mechanisms
have been elucidated here, while for others, notably regard-
ing the effects on Tg iodination, further studies will be nee-
ded in the future. First, Nrf2 directly upregulates the
transcription of the Tg gene via binding to two AREs in its
upstream enhancer, which are conserved between rodents
and human. Nrf2 thus emerges as the first ubiquitous tran-
scription factor to regulate Tg expression. Interestingly, Nrf2
mRNA levels in the adult human thyroid are among the
highest compared to other tissues (Human Protein Atlas;
https://www.proteinatlas.org/ENSG00000116044-NFE2L2/
tissue#gene_information) (53). Also, during mouse devel-
opment, the timing of first Nrf2 mRNA detection in the
thyroid gland (E14.5) coincides perfectly with that of Tg
(E14.5), whereas Ttf1 mRNA is already expressed in the
gland from E12.5 (mouse Gene Expression Database, http://
www.informatics.jax.org/gxd) (54). Even though patterns
suggestive of increased degradation of Tg were not observed
in the Nrf2 KO mice, the present data do not exclude
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additional mechanisms that might contribute to the lower Tg
levels observed in the Nrf2 KO mice, such as altered pro-
cessing (55).
Regulation of Tg by a redox-responsive transcription
factor makes biological sense because not only Tg iodination
but also Tg folding processes are mediated by oxidation re-
actions. Thus, regulation of both Tg production and antiox-
idant defense by Nrf2 likely facilitates the coordination of
these processes in order to ensure normal follicular function
with optimal Tg economy. Indeed, the second function of
Nrf2 under normal conditions is to prevent excessive Tg io-
dination. Previous studies indicate that excess iodination
A B
C
FIG. 7. Evolutionary conservation of the upstream Tg enhancer and regulation of its activity by direct binding of Nrf2 to
two conserved AREs. (A) Schematic representation of the organization of the human TG proximal promoter and upstream
enhancer. The relative positions of two newly identified AREs (ARE1 and ARE2) sites are shown (green), along with
known high-affinity TTF1 binding sites (red) and a putative CRE-like site (yellow). (B) Functional analysis of ARE binding
sites in the human Tg upstream enhancer. PCCL3 cells cultured in complete medium in 96-well plates were transfected as
indicated with different constructs of human Tg promoter/enhancer (pTg) either WT or mutated in the core ARE1 or ARE2
sequences (mut_ARE1 and mut_ARE2, respectively) or in both (mut_ARE1/2). Cells were treated 24 hours later with 5 lM
of SLF or vehicle (<0.1% dimethyl sulfoxide), and lysed 24 hours later to measure luciferase activity. Co-transfected
pEGFP-N1 plasmid and renilla luciferase pRLTK-DARE plasmids allowed to evaluate the transfection efficiency and to
normalize the luciferase activities, respectively. Results are presented as fold change over the normalized activity of the WT
pTg construct. Error bars indicate means – standard deviation of at least three independent experiments. *p < 0.05 vs. WT;xp < 0.05 vs. WT + SLF; #p < 0.05 vs. mut_ARE2; n.s., not significant. (C) Functional validation of ARE1 and ARE2 as Nrf2
binding sites in the rat Tg upstream enhancer. WT or Nrf2-KO (KO) PCCL3 cells cultured in complete medium were treated
with SLF or vehicle for 24 hours, as in (B). Chromatin was immunoprecipitated using a rabbit anti-Nrf2 antibody validated
for ChIP or a control rabbit IgG. Immunoprecipitated DNA was quantified by real-time RT-PCR using primers flanking the
homologous ARE1 or ARE2 site in the rat Tg enhancer. The validated ARE in the rat Nqo1 promoter served as positive
control, while an unrelated sequence downstream of the Actb gene served as negative control. Quantified DNA for each
target was normalized to corresponding input DNA, and the results were plotted as fold enrichment of the target sequence
over the negative control target. Error bars indicate means – standard deviation of at least three independent experiments.
*p < 0.05 vs. respective IgG control; xp< 0.05 vs. respective Nrf2 untreated; n.s., not significant.
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within the thyrocyte is apparently avoided by controlling the
intracellular availability of H2O2 through glutathione per-
oxidase activity (56), and thioredoxin reductase has also been
proposed as a means for the thyroid to detoxify H2O2 (57).
The findings show that both these enzymes (Gpx2 and
Txnrd1) are positively regulated by Nrf2, supporting a
possible mechanistic link between Nrf2 and inhibition of
Tg iodination metabolism. Thus, it is speculated that this
might be mediated by a reduction of basal ROS levels via
the control of the basal transcription of antioxidant genes
(Fig. 8). However, previous work has shown that treatment of
WT mice with the ROS scavenger NAC does not eliminate
iodinated Tg from thyroid follicles (58). Thus, further work is
necessary to elucidate the underlying mechanism. Because
Tg iodination requires the 3D structure of the follicle, it
cannot be modeled properly in conventional 2D cultures of
thyroid follicular cells. The possibility of creating stem cell–
derived 3D functional follicles (59) should make it possible
to test the underlying mechanism of increased Tg iodination
in Nrf2 KO thyroids in the near future.
Considering that Nrf2 has an impact on both total Tg levels
and iodinated Tg levels, it is remarkable that ubiquitous and
ts-Nrf2 KO mice are neither hyper- nor hypothyroid. The
observed euthyroidism suggests that the levels of total Tg
and iodinated Tg are in fact in a dynamic equilibrium. This
would allow the thyroid to employ Nrf2-mediated antioxi-
dant responses to preserve redox homeostasis, despite being
constantly exposed to pro-oxidant substances such as H2O2,
which is necessary for its physiological function, while at the
same time maintaining normal levels of thyroid hormone
production. This equilibrium is partly mediated by the reg-
ulatory actions of Nrf2 on Tg and ROS, but also apparently by
a Nrf2-independent mechanism, since the equilibrium is also
maintained under the extreme setting of absent Nrf2 activity
(Fig. 8). Tg itself is a candidate mediator of this effect, since it
has been proposed to exert multiple autoregulatory functions
in thyroid follicles (60). Alternatively, altered processing of
iodinated Tg in Nrf2 KO mice is another possibility that
might explain the euthyroid state of the animals. Nrf2 KO
mice can now serve as a sensitized background for further
studies to elucidate such thyroid homeostatic mechanisms.
Third, the present data indicate that the antioxidant func-
tion of Nrf2 is even more important under conditions of
iodide overload, which further activate Nrf2 and its tran-
scriptional program to limit ROS levels and thereby prevent
oxidative damage to biomolecules of follicular cells, and
potentially contribute to the autoregulatory reduction in H2O2
levels in response to high iodide (46). This latter mechanism
may account for the fourth effect of Nrf2, namely its con-
tribution to the inhibition of Tg iodination under iodide
challenge. While it is known that iodide overload inhibits
thyroperoxidase (TPO) activity via iodide intermediates such
as 2-IHDA (61), this effect (the so-called Wolff–Chaikoff
phenomenon) (47) is not yet fully elucidated. It is speculated
that Nrf2, via control of ROS levels and/or other mechanisms,
may impact the levels of 2-IHDA or other iodolipids that
inhibit TPO activity. The availability of Nrf2 KO rats (62,63),
with their bigger thyroid size that can facilitate biochemical
studies, offers an opportunity to investigate the mechanism
by which Nrf2 impacts iodide metabolism under basal con-
ditions and during iodide excess.
In contrast to Tg, which is directly regulated by Nrf2, other
genes central to thyroid follicular cell specification, differ-
entiation, and/or function were not impacted by Nrf2 in ways
indicating direct regulation. Some of them may be impacted
indirectly as a result of the effect of the crosstalk of Nrf2 with
other pathways or due to the general functional status of
the cell. This might explain, for example, the differences
observed between ubiquitous and thyroid-specific Nrf2 KO
mice in the mRNA levels of Duox1 and Duoxa1 compared
to respective controls. Similarly, Nis levels were either not
impacted in Nrf2 loss-of-function conditions or showed a
mild tendency toward lower levels, which is also suggestive
of an indirect effect. Interestingly, the fact that total T4 levels
were similar to controls in ts-Nrf2 KO mice but higher than
controls in ubiquitous Nrf2 KO mice is suggestive of a pos-
sible role of Nrf2 in deiodinase expression and/or activity,
consistent with the presence of a highly conserved putative
ARE sequence of yet unknown functionality in the upstream
region of the DIO2 gene (64). However, lower mRNA levels
ofDio2were not observed in the Nrf2 KOmice or ts-Nrf2 KO
mice, but a tendency for lower Dio1 mRNA levels was ob-
served in Nrf2 loss-of-function conditions in mice and cells.
Lastly, Tpo levels did not show significant differences in
Table 2. Summary of the Main Findings in Cell Lines
Nrf2 KO Keap1 KO
Tg mRNA Y [
Tg protein Y [
Nqo1 (Gpx2, Txrnd1) mRNA Y [
ROS [ Y
ARE basal activity Y n.t.
ARE inducible activity Y n.t.
Nrf2 binding to Tg AREs YY n.t.
Arrows indicate changes compared to WT cells; n.t., not tested.
ROS, reactive oxygen species; ARE, antioxidant response
element.
Nrf2
basal conditions iodide overload
Tg availability for thyroid 
hormone synthesis inhibition of Tg iodination
Tg transcription
basal antioxidant
gene transcription
ROS
prevention of excessive
Tg iodination
inducible antioxidant
gene transcription
ROS
prevention of intrathyroidal
oxidative damage
ROS
FIG. 8. Schematic representation of demonstrated and
proposed pleitropic functions of Nrf2 in follicular thyroid
cells under basal conditions and in response to iodide over-
load. The solid arrows indicate mechanisms sufficiently
demonstrated in the present work. The dotted arrows indicate
putative mechanisms that require further investigation.
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mice but showed consistently lower levels in Keap1 KO cells,
arguing against direct regulation by Nrf2.
Recently, it was shown that in mice lacking Nis but pro-
vided with high doses of iodide, Tg iodination and thyroid
hormone synthesis can proceed successfully to a certain de-
gree (65). In that setting, a decrease in the mRNA levels of
Nrf2 and various antioxidant genes was observed in associ-
ation with high TSH levels, raising the possibility that TSH
represses Nrf2 to increase ROS levels, thereby favoring the
oxidative reactions required for Tg iodination and thyroid
hormone synthesis (65). In the present work, patterns were
observed in TSH-treated cells that are consistent with this
hypothesis, including slightly reduced Nrf2 mRNA levels,
increased Keap1 mRNA levels, and reduced ARE activ-
ity. The availability of the tool set described here, notably
the Nrf2 KO and Keap1 KO cells, will allow the mecha-
nisms by which TSH impacts Nrf2 signaling to be further
characterized.
The demonstration that Nrf2 has hitherto unrecognized
roles in the thyroid opens a wide field for further investiga-
tions into the relationship between antioxidant defense
and thyroid pathophysiology. For example, it has been well
documented that increased Tg iodination facilitates proces-
sing and presentation of a cryptic pathogenic peptide, sug-
gesting a mechanism that can at least in part account for the
association of high iodide intake with the development of
autoimmune thyroid disease (66). Interestingly, when Nrf2
KO mice are bred into autoimmunity-permissive genetic
backgrounds, a subset of them develop a multi-organ auto-
immune syndrome (67–69), but the involvement of the thy-
roid has not been examined. It will thus be interesting to test
whether Nrf2 KO mice in an appropriate background de-
velop thyroid autoimmunity either spontaneously or when
exposed chronically to excess iodide, as well as to investigate
whether functional polymorphisms in the gene encoding Nrf2
in humans (NFE2L2) are associated with autoimmune Ha-
shimoto’s thyroiditis. In addition, two recent case reports
have associated loss-of-function mutations in KEAP1 with
goiter (thyroid enlargement) in respective families (70,71).
The finding of increased Tg levels in Keap1 KO cells sug-
gests that this may be a mechanism contributing to the goiter
phenotype. It is therefore relevant to phenotype in future
work thyroid anatomy and function in Keap1 hypomorphic
mice, in which Nrf2 is constitutively activated at moderate
levels (72). Lastly, dietary antioxidants activating Nrf2, such
as sulforaphane, are being clinically tested for the chemo-
prevention of diseases associated with oxidative stress
(73,74). Yet, their potential beneficial, detrimental, or neutral
effects on the thyroid have not been characterized. In this
sense, it will be interesting to test thyroid function among
participants in sulforaphane clinical trials.
To conclude, the relationship between iodide, Tg, oxida-
tive stress, and Nrf2 is also interesting from an evolutionary
perspective. Studies in kelp have shown that iodide has
ancestral roles in redox homeostasis, including scavenging
of atmospheric ozone (75). Nrf2 homologues with antioxi-
dant functions are also ancient, appearing first in fungi
around 1.5 billion years ago when photosynthetic oxygen
was being absorbed into the oceans (76). In contrast, Tg
appears to represent a novel molecular architecture elabo-
rated as a single event at the base of vertebrates and virtually
unchanged thereafter (77). Thus, it is speculated that after
thyroid, Tg, and Tg iodination appeared during evolution, it
was beneficial to adapt Nrf2 beyond its established antiox-
idant function to regulate Tg expression and iodination in
harmony with the redox status of the thyroid follicular cells.
Acknowledgments
We are grateful to Prof. Roberto Di Lauro, Prof. Gabriella
De Vita, Prof. Michael Sporn, and Dr. Nobunao Wakabayashi
for providing valuable reagents, as well as to Prof. Dionysios
Papachristou, Dr. Stavroula Manolakou, and Dr. Ioannis Lilis
for expert technical assistance. This work was supported
by Swiss National Science Foundation Research Grant
31003A_153062; Leenaards Foundation 2016 Fellowship
for Academic Promotion in Clinical Medicine; Swiss Na-
tional Science Foundation—State Secretariat for Education,
Research and Innovation (SNF-COST) Project 174626—
C15.0045; 3R Foundation Switzerland Project Grant 146-15;
the Swiss Society for Endocrinology-Diabetology 2014Young
Independent Investigator Award; Marie Curie International
Reintegration Grant 268266 (all to G.P.S.); and by grant
R37DK15070 from the National Institutes of Health (to S.R.).
The content is solely the responsibility of the authors and
does not necessarily represent the official views of the
funding agencies. The work benefited from COST Actions
BM1307 (PROTEOSTASIS) and CA16112 (NutRedOx),
both supported by European Cooperation in Science and
Technology (COST).
Author Disclosure Statement
The authors have nothing to disclose.
References
1. Halliwell B 2007 Biochemistry of oxidative stress. Bio-
chem Soc Trans 35:1147–1150.
2. Jones DP 2006 Redefining oxidative stress. Antioxid Redox
Signal 8:1865–1879.
3. Maier J, van Steeg H, van Oostrom C, Karger S, Paschke R,
Krohn K 2006 Deoxyribonucleic acid damage and spon-
taneous mutagenesis in the thyroid gland of rats and mice.
Endocrinology 147:3391–3397.
4. Leoni SG, Kimura ET, Santisteban P, De la Vieja A 2011
Regulation of thyroid oxidative state by thioredoxin re-
ductase has a crucial role in thyroid responses to iodide
excess. Mol Endocrinol 25:1924–1935.
5. Poncin S, Gerard AC, Boucquey M, Senou M, Calderon
PB, Knoops B, Lengele B, Many MC, Colin IM 2008
Oxidative stress in the thyroid gland: from harmlessness to
hazard depending on the iodine content. Endocrinology
149:424–433.
6. Poncin S, Colin IM, Gerard AC 2009 Minimal oxidative
load: a prerequisite for thyroid cell function. J Endocrinol
201:161–167.
7. Poncin S, Van Eeckoudt S, Humblet K, Colin IM, Gerard
AC 2010 Oxidative stress: a required condition for thyroid
cell proliferation. Am J Pathol 176:1355–1363.
8. Maier J, van Steeg H, van Oostrom C, Paschke R, Weiss
RE, Krohn K 2007 Iodine deficiency activates antioxidant
genes and causes DNA damage in the thyroid gland of rats
and mice. Biochim Biophys Acta 1773:990–999.
9. Krohn K, Maier J, Paschke R 2007 Mechanisms of disease:
hydrogen peroxide, DNA damage and mutagenesis in the
Nrf2 REGULATES ROS AND THYROGLOBULIN IN THYROID 795
D
ow
nl
oa
de
d 
by
 1
68
.9
6.
24
0.
2 
fro
m
 w
w
w
.li
eb
er
tp
ub
.co
m
 at
 0
2/
05
/2
0.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
development of thyroid tumors. Nat Clin Pract Endocrinol
Metab 3:713–720.
10. Motohashi H, Yamamoto M 2004 Nrf2-Keap1 defines
a physiologically important stress response mechanism.
Trends Mol Med 10:549–557.
11. Kang MI, Kobayashi A, Wakabayashi N, Kim SG, Yama-
moto M 2004 Scaffolding of Keap1 to the actin cytoskel-
eton controls the function of Nrf2 as key regulator of
cytoprotective phase 2 genes. Proc Natl Acad Sci U S A
101:2046–2051.
12. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K,
Engel JD, Yamamoto M 1999 Keap1 represses nuclear
activation of antioxidant responsive elements by Nrf2
through binding to the amino-terminal Neh2 domain.
Genes Devel 13:76–86.
13. Dhakshinamoorthy S, Jaiswal AK 2001 Functional char-
acterization and role of INrf2 in antioxidant response
element-mediated expression and antioxidant induction of
NAD(P)H:quinone oxidoreductase1 gene. Oncogene 20:
3906–3917.
14. Katsuoka F, Motohashi H, Ishii T, Aburatani H, Engel JD,
Yamamoto M 2005 Genetic evidence that small maf pro-
teins are essential for the activation of antioxidant response
element-dependent genes. Mol Cell Biol 25:8044–8051.
15. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y,
Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M,
Nabeshima Y 1997 An Nrf2/small Maf heterodimer me-
diates the induction of phase II detoxifying enzyme genes
through antioxidant response elements. Biochem Biophys
Res Commun 236:313–322.
16. Motohashi H, Katsuoka F, Engel JD, Yamamoto M 2004
Small Maf proteins serve as transcriptional cofactors for
keratinocyte differentiation in the Keap1-Nrf2 regulatory
pathway. Proc Natl Acad Sci U S A 101:6379–6384.
17. Sykiotis GP, Bohmann D 2010 Stress-activated cap’n’col-
lar transcription factors in aging and human disease. Sci
Signal 3:re3.
18. Lee JM, Li J, Johnson DA, Stein TD, Kraft AD, Calkins
MJ, Jakel RJ, Johnson JA 2005 Nrf2, a multi-organ pro-
tector? FASEB J 19:1061–1066.
19. Yates MS, Kwak MK, Egner PA, Groopman JD, Bod-
reddigari S, Sutter TR, Baumgartner KJ, Roebuck BD, Liby
KT, Yore MM, Honda T, Gribble GW, Sporn MB, Kensler
TW 2006 Potent protection against aflatoxin-induced tu-
morigenesis through induction of Nrf2-regulated pathways
by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-
dien-28-oyl]imidazole. Cancer Res 66:2488–2494.
20. Xu C, Huang MT, Shen G, Yuan X, Lin W, Khor
TO, Conney AH, Kong AN 2006 Inhibition of 7,12-
dimethylbenz(a)anthracene-induced skin tumorigenesis in
C57BL/6 mice by sulforaphane is mediated by nuclear
factor E2-related factor 2. Cancer Res 66:8293–8296.
21. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto
M, Talalay P, Kensler TW 2001 Sensitivity to carcinogenesis
is increased and chemoprotective efficacy of enzyme inducers
is lost in nrf2 transcription factor-deficient mice. Proc Natl
Acad Sci U S A 98:3410–3415.
22. Wang T, Liang X, Abeysekera IR, Iqbal U, Duan Q, Naha
G, Lin L, Yao X 2017 Activation of the Nrf2-keap 1
pathway in short-term iodide excess in thyroid in rats. Oxid
Med Cell Longev 2017:4383652.
23. Bouchard M, Souabni A, Busslinger M 2004 Tissue-
specific expression of cre recombinase from the Pax8 locus.
Genesis 38:105–109.
24. Reddy NM, Potteti HR, Mariani TJ, Biswal S, Reddy SP
2011 Conditional deletion of Nrf2 in airway epithelium
exacerbates acute lung injury and impairs the resolution of
inflammation. Am J Respir Cell Mol Biol 45:1161–1168.
25. Ferrara AM, Liao XH, Gil-Ibanez P, Marcinkowski T,
Bernal J, Weiss RE, Dumitrescu AM, Refetoff S 2013
Changes in thyroid status during perinatal development
of MCT8-deficient male mice. Endocrinology 154:2533–
2541.
26. Ziros PG, Chartoumpekis DV, Sykiotis GP 2016A simple
protocol for high efficiency protein isolation after RNA
isolation from mouse thyroid and other very small tissue
samples. Methods Mol Biol 1449:383–393.
27. Ziros PG, Manolakou SD, Habeos IG, Lilis I, Chartoum-
pekis DV, Koika V, Soares P, Kyriazopoulou VE, Scopa
CD, Papachristou DJ, Sykiotis GP 2013 Nrf2 is commonly
activated in papillary thyroid carcinoma, and it controls
antioxidant transcriptional responses and viability of cancer
cells. J Clin Endocrinol Metab 98:E1422–1427.
28. Den Hartog MT, De Boer M, Veenboer GJ, De Vijlder
JJ 1990 Generation and characterization of monoclonal
antibodies directed against noniodinated and iodinated
thyroglobulin, among which are antibodies against hor-
monogenic sites. Endocrinology 127:3160–3165.
29. Levy O, Dai G, Riedel C, Ginter CS, Paul EM, Lebowitz
AN, Carrasco N 1997 Characterization of the thyroid Na+/I–
symporter with an anti-COOH terminus antibody. Proc Natl
Acad Sci U S A 94:5568–5573.
30. Fusco A, Berlingieri MT, Di Fiore PP, Portella G, Grieco
M, Vecchio G 1987 One- and two-step transformations of
rat thyroid epithelial cells by retroviral oncogenes. Mol
Cell Biol 7:3365–3370.
31. Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong
R, Williams CR, Royce DB, Honda T, Honda Y, Gribble
GW, Hill-Kapturczak N, Agarwal A, Sporn MB 2005 The
synthetic triterpenoids, CDDO and CDDO-imidazolide, are
potent inducers of heme oxygenase-1 and Nrf2/ARE sig-
naling. Cancer Res 65:4789–4798.
32. Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin HA,
Zhang DD 2011 Brusatol enhances the efficacy of che-
motherapy by inhibiting the Nrf2-mediated defense mech-
anism. Proc Natl Acad Sci U S A 108:1433–1438.
33. Pereira A, Braekman JC, Dumont JE, Boeynaems JM 1990
Identification of a major iodolipid from the horse thyroid
gland as 2-iodohexadecanal. J Biol Chem 265:17018–17025.
34. Favreau LV, Pickett CB 1995 The rat quinone reductase
antioxidant response element. Identification of the nucleo-
tide sequence required for basal and inducible activity and
detection of antioxidant response element-binding proteins
in hepatoma and non-hepatoma cell lines. J Biol Chem 270:
24468–24474.
35. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD,
Kang MI, Kobayashi A, Yamamoto M, Kensler TW, Ta-
lalay P 2004 Protection against electrophile and oxidant
stress by induction of the phase 2 response: fate of cyste-
ines of the Keap1 sensor modified by inducers. Proc Natl
Acad Sci U S A 101:2040–2045.
36. Dreos R, Ambrosini G, Groux R, Cavin Perier R, Bucher P
2017 The eukaryotic promoter database in its 30th year:
focus on non-vertebrate organisms. Nucleic Acids Res 45:
D51–D55.
37. Mathelier A, Fornes O, Arenillas DJ, Chen CY, Denay G,
Lee J, Shi W, Shyr C, Tan G, Worsley-Hunt R, Zhang AW,
Parcy F, Lenhard B, Sandelin A, Wasserman WW 2016
796 ZIROS ET AL.
D
ow
nl
oa
de
d 
by
 1
68
.9
6.
24
0.
2 
fro
m
 w
w
w
.li
eb
er
tp
ub
.co
m
 at
 0
2/
05
/2
0.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
JASPAR 2016: a major expansion and update of the open-
access database of transcription factor binding profiles.
Nucleic Acids Res 44:D110–115.
38. Pohlenz J, Dumitrescu A, Zundel D, Martine U, Schon-
berger W, Koo E, Weiss RE, Cohen RN, Kimura S, Re-
fetoff S 2002 Partial deficiency of thyroid transcription
factor 1 produces predominantly neurological defects in
humans and mice. J Clin Invest 109:469–473.
39. Berg V, Vassart G, Christophe D 1996 Identification of a
thyroid-specific and cAMP-responsive enhancer in the up-
stream sequences of the human thyroglobulin promoter.
Biochim Biophys Acta 1307:35–38.
40. Donda A, Javaux F, Van Renterghem P, Gervy-Decoster
C, Vassart G, Christophe D 1993 Human, bovine, canine
and rat thyroglobulin promoter sequences display species-
specific differences in an in vitro study. Mol Cell En-
docrinol 90:R23–26.
41. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu
PD, Wu X, Jiang W, Marraffini LA, Zhang F 2013 Multi-
plex genome engineering using CRISPR/Cas systems.
Science 339:819–823.
42. Wakabayashi N, Shin S, Slocum SL, Agoston ES, Waka-
bayashi J, Kwak MK, Misra V, Biswal S, Yamamoto M,
Kensler TW 2010 Regulation of notch1 signaling by Nrf2:
implications for tissue regeneration. Sci Signal 3:ra52.
43. Runkle EA, Rice SJ, Qi J, Masser D, Antonetti DA, Win-
slow MM, Mu D 2012 Occludin is a direct target of thyroid
transcription factor-1 (TTF-1/NKX2-1). J Biol Chem 287:
28790–28801.
44. Cleries R, Galvez J, Espino M, Ribes J, Nunes V, de
Heredia ML 2012 BootstRatio: a web-based statistical
analysis of fold-change in qPCR and RT-qPCR data using
resampling methods. Comput Biol Med 42:438–445.
45. Eng PH, Cardona GR, Fang SL, Previti M, Alex S, Car-
rasco N, Chin WW, Braverman LE 1999 Escape from the
acute Wolff–Chaikoff effect is associated with a decrease
in thyroid sodium/iodide symporter messenger ribonucleic
acid and protein. Endocrinology 140:3404–3410.
46. Kopp P 2005 Thyroid hormone synthesis. In: Braverman
LE, Utiger RD (eds) Werner and Ingbar’s The Thyroid: A
Fundamental and Clinical Text. Lippincott Williams &
Wilkins, Philadelphia, PA, pp 48–74.
47. Wolff J, Chaikoff IL 1948 Plasma inorganic iodide as a
homeostatic regulator of thyroid function. J Biol Chem 174:
555–564.
48. Santisteban P, Kohn LD, Di Lauro R 1987 Thyroglobulin
gene expression is regulated by insulin and insulin-like
growth factor I, as well as thyrotropin, in FRTL-5 thyroid
cells. J Biol Chem 262:4048–4052.
49. Santisteban P, Acebron A, Polycarpou-Schwarz M, Di
Lauro R 1992 Insulin and insulin-like growth factor I
regulate a thyroid-specific nuclear protein that binds to the
thyroglobulin promoter. Mol Endocrinol 6:1310–1317.
50. Panneels V, Juvenal G, Boeynaems JM, Dumont JE, Van
Sande J 2009 Iodide effects on the thyroid: biochemical,
physiological, pharmacological, and clinical effects of io-
dide in the thyroid. In: Preedy VR, Burrow GN, Watson R
(eds) Comprehensive Handbook of Iodine. Academic Press,
Oxford, pp 303–314.
51. Christophe-Hobertus C, Christophe D 1999 Two binding
sites for thyroid transcription factor 1 (TTF-1) determine
the activity of the bovine thyroglobulin gene upstream
enhancer element. Mol Cell Endocrinol 149:79–84.
52. Berg V, Vassart G, Christophe D 1997A zinc-dependent
DNA-binding activity co-operates with cAMP-responsive-
element-binding protein to activate the human thyroglob-
ulin enhancer. Biochem J 323:349–357.
53. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oks-
vold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E,
Asplund A, Olsson I, Edlund K, Lundberg E, Navani S,
Szigyarto CA, Odeberg J, Djureinovic D, Takanen JO,
Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J,
Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von
Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen
M, von Heijne G, Nielsen J, Ponten F 2015 Proteomics.
Tissue-based map of the human proteome. Science 347:
1260419.
54. Finger JH, Smith CM, Hayamizu TF, McCright IJ, Xu J,
Law M, Shaw DR, Baldarelli RM, Beal JS, Blodgett O,
Campbell JW, Corbani LE, Lewis JR, Forthofer KL, Frost
PJ, Giannatto SC, Hutchins LN, Miers DB, Motenko H,
Stone KR, Eppig JT, Kadin JA, Richardson JE, Ringwald
M 2017 The mouse Gene Expression Database (GXD):
2017 update. Nucleic Acids Res 45:D730–D736.
55. Di Jeso B, Arvan P 2016 Thyroglobulin from molecular
and cellular biology to clinical endocrinology. Endocr Rev
37:2–36.
56. Ekholm R, Bjorkman U 1997 Glutathione peroxidase de-
grades intracellular hydrogen peroxide and thereby inhibits
intracellular protein iodination in thyroid epithelium. En-
docrinology 138:2871–2878.
57. Howie AF, Arthur JR, Nicol F, Walker SW, Beech SG,
Beckett GJ 1998 Identification of a 57-kilodalton seleno-
protein in human thyrocytes as thioredoxin reductase and
evidence that its expression is regulated through the
calcium-phosphoinositol signaling pathway. J Clin En-
docrinol Metab 83:2052–2058.
58. Poncin S, Colin IM, Decallonne B, Clinckspooor I, Many
MC, Denef JF, Gerard AC 2010N-acetylcysteine and 15
deoxy-{delta}12,14-prostaglandin J2 exert a protective ef-
fect against autoimmune thyroid destruction in vivo but not
against interleukin-1{alpha}/interferon {gamma}-induced
inhibitory effects in thyrocytes in vitro. Am J Pathol 177:
219–228.
59. Antonica F, Kasprzyk DF, Opitz R, Iacovino M, Liao XH,
Dumitrescu AM, Refetoff S, Peremans K, Manto M, Kyba
M, Costagliola S 2012 Generation of functional thyroid
from embryonic stem cells. Nature 491:66–71.
60. Sellitti DF, Suzuki K 2014 Intrinsic regulation of thyroid
function by thyroglobulin. Thyroid 24:625–638.
61. Rossich LE, Thomasz L, Nicola JP, Nazar M, Salvarredi LA,
Pisarev M, Masini-Repiso AM, Christophe-Hobertus C,
Christophe D, Juvenal GJ 2016 Effects of 2-iodohexadecanal
in the physiology of thyroid cells. Mol Cell Endocrinol 437:
292–301.
62. Taguchi K, Takaku M, Egner PA, Morita M, Kaneko T,
Mashimo T, Kensler TW, Yamamoto M 2016 Generation
of a new model rat: Nrf2 knockout rats are sensitive to
aflatoxin B1 toxicity. Toxicol Sci 152:40–52.
63. Priestley JR, Kautenburg KE, Casati MC, Endres BT,
Geurts AM, Lombard JH 2016 The NRF2 knockout rat: a
new animal model to study endothelial dysfunction, oxidant
stress, and microvascular rarefaction. Am J Physiol Heart
Circ Physiol 310:H478–487.
64. Wang X, Tomso DJ, Chorley BN, Cho HY, Cheung VG,
Kleeberger SR, Bell DA 2007 Identification of polymor-
Nrf2 REGULATES ROS AND THYROGLOBULIN IN THYROID 797
D
ow
nl
oa
de
d 
by
 1
68
.9
6.
24
0.
2 
fro
m
 w
w
w
.li
eb
er
tp
ub
.co
m
 at
 0
2/
05
/2
0.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
phic antioxidant response elements in the human genome.
Hum Mol Genet 16:1188–1200.
65. Ferrandino G, Kaspari RR, Reyna-Neyra A, Boutagy NE,
Sinusas AJ, Carrasco N 2017 An extremely high dietary
iodide supply forestalls severe hypothyroidism in Na+/I–
symporter (NIS) knockout mice. Sci Rep 7:5329.
66. Dai YD, Rao VP, Carayanniotis G 2002 Enhanced iodin-
ation of thyroglobulin facilitates processing and presentation
of a cryptic pathogenic peptide. J Immunol 168:5907–5911.
67. Yoh K, Itoh K, Enomoto A, Hirayama A, Yamaguchi N,
Kobayashi M, Morito N, Koyama A, Yamamoto M, Takahashi
S 2001 Nrf2-deficient female mice develop lupus-like
autoimmune nephritis. Kidney Int 60:1343–1353.
68. Li J, Stein TD, Johnson JA 2004 Genetic dissection
of systemic autoimmune disease in Nrf2-deficient mice.
Physiol Genomics 18:261–272.
69. Ma Q, Battelli L, Hubbs AF 2006 Multiorgan autoimmune
inflammation, enhanced lymphoproliferation, and impaired
homeostasis of reactive oxygen species in mice lacking the
antioxidant-activated transcription factor Nrf2. Am J Pathol
168:1960–1974.
70. Teshiba R, Tajiri T, Sumitomo K, Masumoto K, Taguchi T,
Yamamoto K 2013 Identification of a KEAP1 germline
mutation in a family with multinodular goitre. PloS One 8:
e65141.
71. Nishihara E, Hishinuma A, Kogai T, Takada N, Hirokawa
M, Fukata S, Ito M, Yabuta T, Nishikawa M, Nakamura H,
Amino N, Miyauchi A 2016A novel germline mutation of
KEAP1 (R483H) associated with a non-toxic multinodular
goiter. Front Endocrinol (Lausanne) 7:131.
72. Taguchi K, Maher JM, Suzuki T, Kawatani Y, Motohashi
H, Yamamoto M 2010 Genetic analysis of cytoprotective
functions supported by graded expression of Keap1. Mol
Cell Biol 30:3016–3026.
73. Egner PA, Chen JG, Wang JB, Wu Y, Sun Y, Lu JH, Zhu J,
Zhang YH, Chen YS, Friesen MD, Jacobson LP, Munoz A,
Ng D, Qian GS, Zhu YR, Chen TY, Botting NP, Zhang Q,
Fahey JW, Talalay P, Groopman JD, Kensler TW 2011
Bioavailability of sulforaphane from two broccoli sprout
beverages: results of a short-term, cross-over clinical trial
in Qidong, China. Cancer Prev Res 4:384–395.
74. Yang L, Palliyaguru DL, Kensler TW 2016 Frugal che-
moprevention: targeting Nrf2 with foods rich in sulfor-
aphane. Semin Oncol 43:146–153.
75. Kupper FC, Carpenter LJ, McFiggans GB, Palmer CJ,
Waite TJ, Boneberg EM, Woitsch S, Weiller M, Abela R,
Grolimund D, Potin P, Butler A, Luther GW 3rd, Kroneck
PM, Meyer-Klaucke W, Feiters MC 2008 Iodide accumu-
lation provides kelp with an inorganic antioxidant impact-
ing atmospheric chemistry. Proc Natl Acad Sci U S A 105:
6954–6958.
76. Gacesa R, Dunlap WC, Barlow DJ, Laskowski RA, Long
PF 2016 Rising levels of atmospheric oxygen and evolution
of Nrf2. Sci Rep 6:27740.
77. Holzer G, Morishita Y, Fini JB, Lorin T, Gillet B, Hughes
S, Tohme M, Deleage G, Demeneix B, Arvan P, Laudet V
2016 Thyroglobulin represents a novel molecular archi-
tecture of vertebrates. J Biol Chem 291:16553–16566.
Address correspondence to:
Gerasimos P. Sykiotis, MD, PhD
Service of Endocrinology, Diabetology and Metabolism
Lausanne University Hospital
Ave de la Sallaz 8, 1011 Lausanne
Switzerland
E-mail: gerasimos.sykiotis@chuv.ch
798 ZIROS ET AL.
D
ow
nl
oa
de
d 
by
 1
68
.9
6.
24
0.
2 
fro
m
 w
w
w
.li
eb
er
tp
ub
.co
m
 at
 0
2/
05
/2
0.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
